A review of new hormonal therapies for prostate cancer in black men: is there enough data?

Meunier, Matthias E; Blanchet, Pascal; Neuzillet, Yann; Lebret, Thierry; Brureau, Laurent

Meunier, Matthias E; Blanchet, Pascal; Neuzillet, Yann; Lebret, Thierry; Brureau, Laurent.

Affiliation

Meunier ME; Department of Urology, Foch Hospital, 40 rue Worth, 92150, Suresnes, France. matthias.meunier@yahoo.fr.
Blanchet P; University of Versailles-Saint-Quentin-en-Yvelines, Versailles, France. matthias.meunier@yahoo.fr.
Neuzillet Y; Department of Urology, Pointe-à-Pitre University Hospital, Pointe-à-Pitre, Guadeloupe, France.
Lebret T; Inserm, UMR_S 1085 - IRSET, Pointe-à-Pitre, Guadeloupe, France.
Brureau L; Department of Urology, Foch Hospital, 40 rue Worth, 92150, Suresnes, France.

BMC Cancer ; 21(1): 61, 2021 Jan 14.

Article in En | MEDLINE | ID: mdl-33446131

Subject(s)

Antineoplastic Agents, Hormonal/therapeutic use; Black or African American/statistics & numerical data; Prostatic Neoplasms/drug therapy; Humans; Male; Prognosis; Prostatic Neoplasms/pathology; Survival Rate

Key words

Abiraterone; Apalutamide; Black men; Enzalutamide; Hormonotherapy; Prostate Cancer

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Black or African American / Antineoplastic Agents, Hormonal Type of study: Observational_studies / Prognostic_studies / Systematic_reviews Limits: Humans / Male Language: En Journal: BMC Cancer Year: 2021 Document type: Article

Fulltext

XML

PubMed Links

Search on Google